ESMO 2014 Congress
IFEMA – Feria de Madrid, Madrid, Spain, 26-30 September 2014

Press briefing 1
Saturday, 27 September 2014, 8:15-9:00 (CEST)
Moderator: TBC

Programme
The data presented will refer to the following studies:

<table>
<thead>
<tr>
<th>Study Code</th>
<th>Title</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>29LBA</td>
<td>Afatinib versus methotrexate (MTX) as second-line treatment for patient with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) who progressed after platinum-based therapy: primary efficacy results of lux-head &amp; neck 1, a phase III trial</td>
<td>Jean-Pascal Machiels, Cliniques Universitaires St. Luc, Belgium</td>
</tr>
<tr>
<td>267PD</td>
<td>Cancer during pregnancy: A case-control analysis of mental development and cardiac functioning of 38 children prenatally exposed to chemotherapy</td>
<td>Frédéric Amant, University of Leuven, Belgium</td>
</tr>
<tr>
<td>47LBA</td>
<td>Phase 3 (P04832) trial results for rolapitant, a novel NK-1 receptor antagonist, in the prevention of chemotherapy-induced nausea and vomiting (CINV) in subjects receiving cisplatin-based chemotherapy</td>
<td>Martin R. Chasen, Elizabeth Bruyere Hospital Division Of Palliative Care, Canada</td>
</tr>
<tr>
<td>1483PD</td>
<td>Anamorelin for the treatment of cancer anorexia-cachexia in NSCLC: results from the Phase 3 studies ROMANA 1 and 2</td>
<td>Jennifer Temel, Massachusetts General Hospital, United States</td>
</tr>
</tbody>
</table>

Data presented at this Press Briefing is embargoed until Saturday, 27 September 2014 at 9:00 CEST
Educational session for journalists

Saturday, 27 September 2014, 12:15-13:00 (CEST)

RAS Testing in Colorectal Cancer Patients: How to Define an Optimal Treatment Strategy

Moderator: Dirk Arnold

Speakers: Eric Van Cutzem, University of Leuven, Belgium, others to be confirmed

Programme
This session will offer members of the press important insight on the use of RAS testing in colorectal cancer and its impact on patient care:

Details to follow.